Literature DB >> 8270915

Spirometry--acceptability and reproducibility in spinal cord injured subjects.

J Ashba1, E Garshick, C G Tun, S L Lieberman, D F Polakoff, J D Blanchard, R Brown.   

Abstract

The American Thoracic Society (ATS) has formulated guidelines for spirometry. We hypothesized that individuals with SCI (SCI), as a result of weak respiratory muscles, would exhibit poor test acceptability and reproducibility. Seventy-eight SCI subjects (39 with complete SCI) answered a respiratory questionnaire and performed spirometry. Of those with complete SCI, the proportion of subjects which met ATS criteria decreased with higher levels of injury. Poor test performance was not associated with age, respiratory symptoms or muscle fatigue. The most common reason for failing to meet ATS criteria for acceptability was excessive back extrapolated volumes (EBEV). Individuals with efforts that were acceptable except for EBEV and/or for exhalation of less than six seconds had values for forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) that were reproducible. If ATS criteria for acceptable spirometry were used in studying subjects with SCI, individuals producing otherwise reproducible values for FVC and FEV1 would be excluded. We found reproducibility similar to what has been reported in other cohorts and conclude that longitudinal study of respiratory function in SCI is feasible.

Entities:  

Mesh:

Year:  1993        PMID: 8270915     DOI: 10.1080/01952307.1993.11735901

Source DB:  PubMed          Journal:  J Am Paraplegia Soc        ISSN: 0195-2307


  15 in total

1.  Spirometry testing standards in spinal cord injury.

Authors:  Alyson Kelley; Eric Garshick; Erica R Gross; Steven L Lieberman; Carlos G Tun; Robert Brown
Journal:  Chest       Date:  2003-03       Impact factor: 9.410

2.  A prospective assessment of mortality in chronic spinal cord injury.

Authors:  E Garshick; A Kelley; S A Cohen; A Garrison; C G Tun; D Gagnon; R Brown
Journal:  Spinal Cord       Date:  2005-07       Impact factor: 2.772

3.  Factors associated with health-related quality of life in chronic spinal cord injury.

Authors:  Nitin B Jain; Marianne Sullivan; Lewis E Kazis; Carlos G Tun; Eric Garshick
Journal:  Am J Phys Med Rehabil       Date:  2007-05       Impact factor: 2.159

4.  Plasma Leptin and Reduced FEV1 and FVC in Chronic Spinal Cord Injury.

Authors:  Eric Garshick; Palak Walia; Rebekah L Goldstein; Merilee Teylan; Antonio A Lazzari; Carlos G Tun; Jaime E Hart
Journal:  PM R       Date:  2017-08-19       Impact factor: 2.298

5.  Determinants of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC in chronic spinal cord injury.

Authors:  Nitin B Jain; Robert Brown; Carlos G Tun; David Gagnon; Eric Garshick
Journal:  Arch Phys Med Rehabil       Date:  2006-10       Impact factor: 3.966

6.  Risk factors for chest illness in chronic spinal cord injury: a prospective study.

Authors:  Kelly L Stolzmann; David R Gagnon; Robert Brown; Carlos G Tun; Eric Garshick
Journal:  Am J Phys Med Rehabil       Date:  2010-07       Impact factor: 2.159

7.  Associations with chest illness and mortality in chronic spinal cord injury.

Authors:  Valery A Danilack; Kelly L Stolzmann; David R Gagnon; Robert Brown; Carlos G Tun; Leslie R Morse; Eric Garshick
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

8.  Longitudinal change in FEV1 and FVC in chronic spinal cord injury.

Authors:  Kelly L Stolzmann; David R Gagnon; Robert Brown; Carlos G Tun; Eric Garshick
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

9.  Determinants of lung volumes in chronic spinal cord injury.

Authors:  Evan L Stepp; Robert Brown; Carlos G Tun; David R Gagnon; Nitin B Jain; Eric Garshick
Journal:  Arch Phys Med Rehabil       Date:  2008-08       Impact factor: 3.966

10.  Breathing pattern and ventilatory control in chronic tetraplegia.

Authors:  Ann M Spungen; William A Bauman; Marvin Lesser; F Dennis McCool
Journal:  Lung       Date:  2009-10-10       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.